{
    "clinical_study": {
        "@rank": "31957", 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to provide treatment with Nivolumab to subjects with\n      histologically confirmed stage III (unresectable) or stage IV advanced melanoma who have\n      progressed on or after prior treatment with an anti-CTLA4-containing therapy and for\n      subjects with known BRAF mutation, also progressed on or after treatment with a BRAF\n      inhibitor."
        }, 
        "brief_title": "Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody", 
        "condition": "Stage III (Unresectable) or Stage IV Advanced Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  \u2265 18 years of age\n\n          -  Histologically confirmed malignant melanoma, Including mucosal melanoma\n\n          -  Previously treated unresectable med stage III or stage IV melanoma, as per American\n             Joint Committee on Cancer staging system\n\n          -  Eastern Cooperative Oncology Group (ECOG) perform status (PS) 0-1\n\n          -  Progressed on or after prior treatment with an anti-CTLA4-containing therapy and, for\n             subjects with known BRAF mutation, also progressed on or after treatment with a BRAF\n             inhibitor\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases\n\n          -  Life expectancy <6 weeks\n\n          -  Subjects with active, known or suspected autoimmune disease\n\n          -  Subjects with a known history of anti-CTLA-4 therapy related adverse reactions based\n             on the CTCAE v criteria\n\n          -  Any treatment in a Nivolumab clinical trial"
            }, 
            "gender": "Both", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "May 16, 2014", 
        "id_info": {
            "nct_id": "NCT02142218", 
            "org_study_id": "CA209-168"
        }, 
        "intervention": {
            "intervention_name": "Nivolumab", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies", 
                "Antibodies, Monoclonal"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "official_title": "Expanded Access Program With Nivolumab for Subjects With Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma Progressing Post Prior Systemic Treatment Containing an Anti_CTLA-4 Monoclonal Antibody", 
        "overall_contact": {
            "email": "Clinical.Trials@bms.com", 
            "last_name": "Please contact:"
        }, 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Available", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ]
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02142218"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "N/A", 
        "study_type": "Expanded Access", 
        "verification_date": "May 2014"
    }
}